Acuitas Investments LLC Raises Stock Position in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Acuitas Investments LLC increased its stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 24.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 407,343 shares of the medical instruments supplier’s stock after buying an additional 80,827 shares during the quarter. Acuitas Investments LLC owned about 0.94% of Harvard Bioscience worth $1,161,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of HBIO. AMH Equity Ltd raised its position in Harvard Bioscience by 7.5% during the 1st quarter. AMH Equity Ltd now owns 2,324,200 shares of the medical instruments supplier’s stock worth $9,855,000 after buying an additional 161,307 shares during the last quarter. Vanguard Group Inc. raised its position in Harvard Bioscience by 2.4% during the first quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock valued at $9,125,000 after acquiring an additional 49,576 shares in the last quarter. Heartland Advisors Inc. lifted its holdings in Harvard Bioscience by 2.6% in the first quarter. Heartland Advisors Inc. now owns 889,133 shares of the medical instruments supplier’s stock valued at $3,770,000 after acquiring an additional 22,666 shares during the period. Bank of New York Mellon Corp grew its position in Harvard Bioscience by 13.0% during the second quarter. Bank of New York Mellon Corp now owns 274,635 shares of the medical instruments supplier’s stock valued at $783,000 after buying an additional 31,505 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of Harvard Bioscience by 193.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock valued at $649,000 after purchasing an additional 150,218 shares in the last quarter. 80.87% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Harvard Bioscience news, CEO James W. Green bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 13th. The shares were purchased at an average price of $2.91 per share, with a total value of $29,100.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,111,091 shares of the company’s stock, valued at approximately $9,053,274.81. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 9.00% of the stock is owned by company insiders.

Harvard Bioscience Stock Down 0.7 %

HBIO stock opened at $2.73 on Friday. Harvard Bioscience, Inc. has a 12 month low of $2.61 and a 12 month high of $5.56. The company has a market cap of $118.56 million, a price-to-earnings ratio of -13.65 and a beta of 1.30. The company has a current ratio of 2.05, a quick ratio of 0.94 and a debt-to-equity ratio of 0.48. The firm has a 50-day moving average of $3.00 and a two-hundred day moving average of $3.50.

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.06). Harvard Bioscience had a negative net margin of 10.56% and a negative return on equity of 2.70%. The business had revenue of $23.10 million during the quarter, compared to analyst estimates of $29.91 million. As a group, analysts forecast that Harvard Bioscience, Inc. will post 0.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com downgraded Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.